炎症性肠病中肠易激综合征型症状6年纵向随访的自然史及影响
在二级医疗的炎症性肠病患者中,应用罗马III标准在基线、2年和6年评估肠易激综合征型症状的自然史。125例三次均有数据的患者中,仅41例(32.8%)从未报告症状;症状与需要糖皮质激素或疾病活动、升级治疗、住院或肠切除无关,但与更多门诊就诊和内镜检查、更差的焦虑抑郁躯体症状及生活质量评分相关。
要点
- 超过三分之二炎症性肠病患者在>6年随访期间出现肠易激综合征型症状。
- 肠易激综合征型症状未增加糖皮质激素使用、疾病活动、升级治疗、住院或肠切除风险。
- 肠易激综合征型症状与门诊就诊和内镜检查次数增加及焦虑、抑郁、躯体症状评分更差、生活质量评分更低相关。
核心结论
- 肠易激综合征型症状影响超过三分之二的炎症性肠病患者,随访>6年,与医疗资源使用增加及更差的焦虑、抑郁、躯体症状和生活质量评分相关,但不与不良疾病活动结局相关。
研究设计与样本
- 纵向随访研究,在二级医疗中纳入炎症性肠病患者,应用罗马III标准在基线、2年和6年评估肠易激综合征型症状。
- 125例在三个时间点均有罗马III数据的个体纳入自然史分析;超过300例有疾病活动数据的患者纳入疾病活动分析。
主要发现
- 125例中仅41例(32.8%)从未报告肠易激综合征型症状;15例(12.0%)基线有症状后缓解,19例(15.2%)症状波动,35例(28.0%)新发症状,15例(12.0%)症状持续。
- 在超过300例有疾病活动数据的患者中,肠易激综合征型症状与需要糖皮质激素或疾病活动、升级治疗、住院或肠切除的可能性增加无关。
- 有肠易激综合征型症状者的平均门诊就诊次数和内镜检查次数显著更高;研究中至少一次报告症状者的焦虑、抑郁和躯体症状评分显著更高,生活质量评分显著更低。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The long-term natural history and impact of irritable bowel syndrome (IBS)-type symptoms on outcomes in inflammatory bowel disease (IBD) are uncertain. AIM: To assess this in a longitudinal follow-up study of patients in secondary care METHODS: We assessed the natural history of IBS-type symptoms in IBD via Rome III criteria applied at baseline, and 2 and 6 years. We defined longitudinal disease activity as the need for glucocorticosteroids or flare, escalation, hospitalisation or intestinal resection. To assess healthcare utilisation, we recorded the number of outpatient clinic attendances and investigations. We also collected anxiety, depression and somatoform symptom scores and quality of life scores during follow-up. RESULTS: Among 125 individuals with Rome III data at all three time points, only 41 (32.8%) never reported IBS-type symptoms. Fifteen patients (12.0%) had IBS-type symptoms at baseline that resolved, 19 (15.2%) had fluctuating symptoms, 35 (28.0%) had new-onset symptoms, and 15 (12.0%) had persistent symptoms. Among more than 300 patients with IBD activity data, IBS-type symptoms were not associated with an increased likelihood of the need for glucocorticosteroids or flare, escalation, hospitalisation or intestinal resection. However, the mean numbers of outpatient appointments and endoscopic investigations were significantly higher among those with IBS-type symptoms. Anxiety, depression and somatoform symptom scores were significantly higher, and quality of life scores were significantly lower, in those reporting IBS-type symptoms at least once during the study. CONCLUSIONS: IBS-type symptoms affected more than two-thirds of patients with IBD during >6 years of follow-up and were associated with increased healthcare utilisation, and worse anxiety, depression, somatoform symptom and quality of life scores, but not adverse disease activity outcomes.
引用
- Fairbrass KM, Hamlin PJ, Gracie DJ, et al. Natural history and impact of irritable bowel syndrome-type symptoms in inflammatory bowel disease during 6 years of longitudinal follow-up. Aliment Pharmacol Ther. 2022. PMID: 35995729. doi:10.1111/apt.17193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。